Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Reducing Adverse Effects … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia

Artikel i vetenskaplig tidskrift
Författare H. Rydholm
Fredrik von Corswant
H. Denison
J. M. Jensen
Anders Lehmann
Magnus Ruth
E. Soderlind
A. Aurell-Holmberg
Publicerad i Clinical Therapeutics
Volym 38
Nummer/häfte 4
Sidor 946-960
ISSN 0149-2918
Publiceringsår 2016
Publicerad vid Institutionen för neurovetenskap och fysiologi
Institutionen för kliniska vetenskaper, Avdelningen för öron-, näs- och halssjukdomar
Sidor 946-960
Språk en
Länkar dx.doi.org/10.1016/j.clinthera.2016...
Ämnesord gamma-aminobutyric acid (GABA)(B) receptor agonist, adverse-effect, formulation development, gastroesophageal-reflux disease, esophageal sphincter relaxations, pump, inhibitor therapy, controlled-trial, volunteers, mechanism, symptoms, agonist, Pharmacology & Pharmacy
Ämneskategorier Klinisk medicin

Sammanfattning

Purpose: Lesogaberan, a gamma-aminobutyric acid (GABA)(B) receptor agonist, was developed for the treatment of gastroesophageal reflux disease in patients with a partial response to proton pump inhibitor therapy. A high prevalence of paresthesia was observed in healthy individuals after dosing with lesogaberan in early-phase clinical trials. The aim of this review was to gain further insight into paresthesia caused by lesogaberan by summarizing the relevant preclinical and clinical data. Methods: This study was a narrative review of the literature and unpublished data. Findings: The occurrence of paresthesia may depend on the route or rate of drug administration; several studies were conducted to test this hypothesis, and formulations were developed to minimize the occurrence of paresthesia. Phase I clinical studies showed that, in healthy individuals, paresthesia occurred soon after administration of lesogaberan in a dose-dependent manner regardless of the route of administration. The occurrence of paresthesia could be decreased by fractionating the dose or reducing the rate of administration. These findings suggest that the initial rate of absorption plays an important part in the development of paresthesia. Modified-release formulations minimize the occurrence of paresthesia while retaining the anti-reflux activity of the drug, as measured by esophageal pH and the number of transient lower esophageal sphincter relaxations. Implications: The development of lesogaberan was halted because the effect on gastroesophageal reflux disease symptoms observed in Phase II studies was not considered clinically meaningful in the target patient population. Nevertheless, it is an example of successful formulation development designed to minimize the occurrence of a compound's adverse effect while retaining its pharmacodynamic action. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?